ovary cancer
Recently Published Documents


TOTAL DOCUMENTS

92
(FIVE YEARS 30)

H-INDEX

12
(FIVE YEARS 2)

2021 ◽  
pp. 161-175
Author(s):  
Bimal Prasad Jit ◽  
Biswajita Padhan ◽  
Ashok Sharma
Keyword(s):  

2021 ◽  
pp. 179-181
Author(s):  
Francisca Fernanda Barbosa Oliveira ◽  
Maria Júlia Barbosa Bezerra ◽  
Isabelle Joyce de Lima Silva-Fernandes ◽  
Deysi Viviana Tenazoa Wong ◽  
Paulo Goberlânio de Barros Silva ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (18) ◽  
pp. 4686
Author(s):  
Aida Barreiro-Alonso ◽  
Mónica Lamas-Maceiras ◽  
Lidia Lorenzo-Catoira ◽  
Mercedes Pardo ◽  
Lu Yu ◽  
...  

This study reports the HMGB1 interactomes in prostate and ovary cancer cells lines. Affinity purification coupled to mass spectrometry confirmed that the HMGB1 nuclear interactome is involved in HMGB1 known functions such as maintenance of chromatin stability and regulation of transcription, and also in not as yet reported processes such as mRNA and rRNA processing. We have identified an interaction between HMGB1 and the NuRD complex and validated this by yeast-two-hybrid, confirming that the RBBP7 subunit directly interacts with HMGB1. In addition, we describe for the first time an interaction between two HMGB1 interacting complexes, the septin and THOC complexes, as well as an interaction of these two complexes with Rab11. Analysis of Pan-Cancer Atlas public data indicated that several genes encoding HMGB1-interacting proteins identified in this study are dysregulated in tumours from patients diagnosed with ovary and prostate carcinomas. In PC-3 cells, silencing of HMGB1 leads to downregulation of the expression of key regulators of ribosome biogenesis and RNA processing, namely BOP1, RSS1, UBF1, KRR1 and LYAR. Upregulation of these genes in prostate adenocarcinomas is correlated with worse prognosis, reinforcing their functional significance in cancer progression.


Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2711
Author(s):  
Angela R. Solano ◽  
Pablo G. Mele ◽  
Fernanda S. Jalil ◽  
Natalia C. Liria ◽  
Ernesto J. Podesta ◽  
...  

Gene/s sequencing in hereditary breast/ovary cancer (HBOC) in routine diagnosis is challenged by the analysis of panels. We aim to report a retrospective analysis of BRCA1/2 and non-BRCA gene sequencing in patients with breast/ovary cancer (BOC), including triple-negative breast cancer (TNBC), in our population. In total 2155 BOC patients (1900 analyzed in BRCA1/2 and 255 by multigenic panels) gave 372 (17.2.6%) and 107 (24.1%) likely pathogenic/pathogenic variants (LPVs/PVs), including BRCA and non-BRCA genes, for the total and TNBC patients, respectively. When BOC was present in the same proband, a 51.3% rate was found for LPVs/PVs in BRCA1/2. Most of the LPVs/PVs in the panels were in BRCA1/2; non-BRCA gene LPVs/PVs were in CDH1, CHEK2, CDKN2A, MUTYH, NBN, RAD51D, and TP53. TNBC is associated with BRCA1/2 at a higher rate than the rest of the breast cancer types. The more prevalent PVs in BRCA1/2 genes (mostly in BRCA1) do not rule out the importance to panels of genes, although they are certainly far from shedding light on the gap of the 85% predicted linkage association of BOC with BRCA1/2 and are still not elucidated.


2021 ◽  
Author(s):  
Lady Feren Pangjaya ◽  
Sanya Khaerunnisa ◽  
Nuzli Fahdia Mazfufah ◽  
Retno Lestari Budiman ◽  
Radiana Dhewayani Antarianto

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Mi Ju Kim ◽  
Ki-Su Park ◽  
Kyoung-Tae Kim ◽  
Eun Young Gil

Abstract Background Fascin is an actin-binding protein and highly expressed in ovarian cancer cells. It is associated with metastasis of cancer and may be a useful prognostic factor. Anticancer activity of curcumin is related to its effect on several signaling mechanisms. Although there have been many reports regarding the anticancer properties of curcumin, its inhibitory effects on migration and invasion of ovarian cancer cells, particularly in the context of fascin expression, have not been reported. The purpose of this study was to investigate the effect of curcumin on fascin expression in ovarian cancer cells and to propose a possible mechanism for the anticancer activity of curcumin through reduced fascin expression. Methods SKOV3, human epithelial ovary cancer cell line, was cultured with curcumin at various dose and duration. The fascin was quantified using cell viability test and Western blot. To determine the effect of curcumin on the upstream pathway of fascin expression, the signal transducer and activator of transcription 3 (STAT3) was analyzed by sandwich-ELISA. Attachment assay, migration assay and invasion assay were analyzed to approve the change of cellular invasiveness of ovary cancer after curcumin. To determine the morphological changes of ovarian cancer cells by curcumin, immunofluorescence was performed. Results MTS assays showed that cell viability was different at various concentration of curcumin, and as concentration increased, cell viability tended to decrease. Curcumin appears to suppress fascin expression, even with a minimal concentration and short exposure time. Also, curcumin may suppress fascin expression in ovarian cancer cells through STAT3 downregulation. The attachment assay, migration assay and invasion assay of the ovarian cancer cells exhibited a statistically significant decrease. Immunofluorescence revealed a change of cell shape from a typical form of uninfluenced cells to a more polygonal appearance, with a significant reduction in filopodia formation. Conclusions Curcumin reduces fascin expression through JAK/STAT3 pathway inhibition, which interferes with the cellular interactions essential for the metastasis and recurrence of ovarian cancer cells. Higher curcumin concentrations and longer exposure times concomitantly decreased fascin expression.


Sign in / Sign up

Export Citation Format

Share Document